Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Abpro Holdings ( (ABP) ) just unveiled an update.
On November 3, 2025, Abpro Holdings, Inc. announced the effectiveness of a 1-for-30 reverse stock split that took place on October 31, 2025. This strategic move aims to maintain compliance with Nasdaq listing requirements and support the company’s growth phase. The reverse stock split reduces the number of outstanding shares from approximately 81.2 million to 2.7 million, with no fractional shares issued. Abpro has achieved a 60% reduction in operating costs and is leveraging its partnership with Celltrion to advance its lead antibody program, ABP-102, with a first-in-human trial expected in 2026. The company’s DiversImmune® and MultiMab™ platforms are also being evaluated to unlock further pipeline value.
The most recent analyst rating on (ABP) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Abpro Holdings stock, see the ABP Stock Forecast page.
More about Abpro Holdings
Abpro Holdings, Inc. is a biotechnology company focused on developing next-generation antibody therapies. The company is advancing a pipeline targeting HER2+ cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration and diabetic macular edema, utilizing its proprietary DiversImmune® platform. Abpro is located in Woburn, Massachusetts.
Average Trading Volume: 5,077,839
Technical Sentiment Signal: Sell
Current Market Cap: $14.79M
See more insights into ABP stock on TipRanks’ Stock Analysis page.